Showing results (151-160 of 171) with videos related to
Sort By:
Pageof 18
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical ArtifactsDaniel Kazdal, Volker Endris, Michael Allgäuer, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.NPJ Precision Oncology|April 1, 2022
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapyTimothy Rajakumar, Rastislav Horos, Julia Jehn, et al.JCO Precision Oncology|November 14, 2025
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule InhibitorFrank W J Heijboer, Marta Brambilla, Mario Occhipinti, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsFelix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.European Journal of Cancer (Oxford, England : 1990)|October 18, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapyFelix Carl Saalfeld, Johanna Möller, Petros Christopoulos, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertionsPetros Christopoulos, Klaus Kluck, Martina Kirchner, et al.JTO Clinical and Research Reports|February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.Pageof 18